184) Further, in a mouse model transfected CAFs |
185) Further, in comparison to the control and |
186) Further, in suspended cells OPN suppresses |
187) umber of new acute cases did not diminish further in spite of ongoing control activi |
188) These data are further supported by immunohistochemical a |
189) The activity was further supported by its considerable iron |
190) ce of an interplay between NO and ROS was further supported by the finding that cryp |
191) m and repetitive nerve stimulation tests, further supported the diagnosis. |
192) pt, an effect that we term the failure-of-further-learning. |
193) n upon MC-LR exposure needs to be studied further. |
194) th high accident risk should be developed further. |
195) Further, a classification analysis indicat |
196) Further, a functional connectivity analysi |
197) Further, a significant (p < 0.01) incre |
198) Further clinical and animal studies should |
199) uld lead to loss of protein function, but further clinical data is required to confi |
200) umor initiating cells and the benefit for further clinical evaluation. |
201) Further evaluation is frequently not perfo |
202) Further evaluation using a better designed |
203) cellular apoptotic machinery necessitates further evaluation. |
204) Further exploration of environmental facto |
205) rTMS represents an approach that deserves further exploration in this regard. |
206) retical and empirical issues that warrant further exploration. |
207) ertain patterns emerged and allowed us to further explore communication events withi |
208) Future studies are needed to further explore the barriers that impede d |
209) nayaur could provide an important data to further explore the taxonomic status of th |
210) Further, for not 1 of the 62 metals are ex |
211) Further, for the very preterm participants |
212) and then ethanol was added and incubated further for 24 h. |
213) left DLPFC and medial frontal cortex, and further increased activation during 2-BACK |
214) In addition, PGI2 overexpression further increased iNOS expression and supe |
215) al [CI] = 1.32-2.34), TT carriers had a further increased risk of AML (OR = 2.67; |
216) We further investigate analytic approaches in |
|